Halozyme Therapeutics Inc
Research Halozyme Therapeutics Inc (HALO) on Bullrun: valuation model: 27.3% overvalued, market cap USD 12.67B, P/E 33.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHALO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal27.3% overvalued
- Market capUSD 12.67B
- P/E33.2
- Financial periodQ2 2026
- RevenueUSD 481.00M
- Net incomeUSD 229.91M
- Free cash flowUSD 236.72M
- Gross margin83.5%
Valuation Snapshot
Bullrun's latest valuation model marks Halozyme Therapeutics Inc as 27.3% overvalued; latest market cap is USD 12.67B; P/E is 33.2.
Peer valuation comparison
Latest P/E is 33.19x versus a Healthcare sector median of 24.6x (34.9% above).
Latest P/E is 33.19x versus a United States median of 23.85x (39.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.40B | USD 316.89M | USD 644.59M | 83.6% | 2.56 | USD 133.82M | USD 2.14B | USD 48.81M |
| FY2024 | USD 1.02B | USD 444.09M | USD 468.37M | 84.3% | 3.43 | USD 115.85M | USD 1.51B | USD 363.82M |
| FY2023 | USD 829.25M | USD 281.59M | USD 373.28M | 76.8% | 2.1 | USD 118.37M | USD 1.50B | USD 83.81M |
| FY2022 | USD 660.12M | USD 202.13M | USD 235.30M | 78.9% | 1.44 | USD 234.20M | USD 1.51B | USD 169.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 12.67B | 33.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.93B | 27.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.89B | 13.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.88B | 19.8 | n/a | n/a |
| 2022 | 2022-12-30 | USD 7.69B | 38.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.53B | 14.6 | n/a | n/a |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
ETFs that hold Halozyme Therapeutics Inc
Halozyme Therapeutics Inc is one of the ten largest holdings of 3 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares Ageing Population UCITS ETF USD (Acc) | 0.76% | 0.40% |
| First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation | 4.42% | 0.60% |
| L&G Pharma Breakthrough UCITS ETF | 3.63% | 0.49% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Halozyme Therapeutics Inc overvalued or undervalued?
Bullrun's valuation model currently marks Halozyme Therapeutics Inc as 27.3% overvalued.
What is Halozyme Therapeutics Inc's market cap?
Halozyme Therapeutics Inc's market capitalization is USD 12.67B.
What is Halozyme Therapeutics Inc's P/E ratio?
Halozyme Therapeutics Inc's price-to-earnings (P/E) ratio is 33.2.
What does Halozyme Therapeutics Inc do?
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.